Table 1 Baseline demographic and clinical characteristics and cardiovascular parameters in sildenafil and control group
|  | Sildenafil (n = 30) | Control (n = 20) | Total study population (n = 50) |
|---|---|---|---|
Age, y | 71 ± 7 | 71 ± 8 | 71 ± 7 |
Men, n (%) | 17 (57) | 7 (35) | 24 (48) |
NYHA II/III, n (%) | 20/10 (67/33) | 13/7 (65/35) | 33/17 (66/34) |
Systolic blood pressure, mm Hg | 130 ± 14 | 127 ± 12 | 129 ± 13 |
Diastolic blood pressure, mm Hg | 80 ± 11 | 76 ± 10 | 78 ± 11 |
Heart rate, bpm | 63 ± 8 | 63 ± 7 | 63 ± 7 |
Body mass index, kg/m2 | 30 ± 6 | 29 ± 4 | 30 ± 5 |
Overweight/obesity (body mass index ≥25 kg/m2), n (%) | 26 (87) | 18 (90) | 44 (88) |
Hypertension (blood pressure ≥ 140/90 mmHg), n (%) | 30 (100) | 20 (100) | 50 (100) |
Paroxysmal atrial fibrillation, n (%) | 10 (33) | 5 (25) | 15 (30) |
Ischemic heart disease, n (%) | 15 (50) | 7 (35) | 22 (44) |
 Previous myocardial infarction, n (%) | 9 (30) | 4 (20) | 13 (26) |
 Myocardial revascularization, n (%) | 11 (37) | 4 (20) | 15 (30) |
Diabetes mellitus, n (%) | 10 (33) | 4 (20) | 14 (28) |
Chronic kidney disease, n (%) | 26 (87) | 14 (70) | 40 (80) |
Drug therapy: | |||
 ACEI/ARB, n (%) | 30 (100) | 20 (100) | 50 (100) |
 β-Blockers, n (%) | 21 (70) | 18 (90) | 39 (78) |
 Diuretics, n (%) | 28 (93) | 19 (95) | 47 (94) |
  Thiazide diuretics, n (%) | 2 (7) | 2 (10) | 4 (8) |
  Loop diuretics, n (%) | 26 (87) | 17 (85) | 34 (86) |
  Spironolactone, n (%) | 6 (20) | 2 (10) | 8 (16) |
 Calcium channel blockers, n (%) | 15 (50) | 7 (35) | 22 (44) |
 Statins, n (%) | 26 (87) | 18 (90) | 44 (88) |
LV ejection fraction, % | 60 ± 5 | 61 ± 6 | 61 ± 5 |
LV hypertrophy, n (%) | 20 (67) | 15 (75) | 35 (70) |
PA systolic pressure, mm Hg | 58.6 ± 14.9 | 55.5 ± 13.5 | 57.3 ± 14.3 |
Increased RA pressure, n (%) | 26 (87) | 14 (70) | 40 (80) |
RV systolic dysfunction, n (%) | 22 (73) | 10 (50) | 32 (64) |
PVR, Wood units | 3.33 ± 0.64 | 3.19 ± 0.47 | 3.27 ± 0.58 |
TPG, mm Hg | 23.3 ± 7.7 | 22.1 ± 8.8 | 22.8 ± 8.1 |
Mitral Е/e′ ratio | 14.2 ± 4.2 | 12.6 ± 3.7 | 13.6 ± 4.0 |
LV diastolic dysfunction, grade II/III, n (%) | 19/11 (64/36) | 14/6 (70/30) | 33/17 (66/34) |
NT-proBNP, pg/mL | 391 (190—582) | 468 (205—720) | 408 (194—631) |